Friday, October 22, 2021

Bayer hits major Roundup setback—again—as judge rejects ‘unreasonable’ $2B settlement

Bayer’s efforts to put an end to the consuming Roundup litigation have hit a wall, raising uncertainties over the weedkiller’s future and its impact on the German conglomerate’s financial position.

A U.S. federal judge in San Francisco on Wednesday rejected Bayer’s already revised $2 billion proposal to settle potential future lawsuits alleging Roundup causes cancer. The deal would have put a halt to litigation over four years, during which time eligible plaintiffs could have received compensation of up to $200,000 each.

In handing down a rejection, U.S. District Judge Vince Chhabria called the plan “clearly unreasonable.” It “would accomplish a lot for Monsanto,” the crop sciences giant Bayer bought in a $63 billion acquisition, but it “would accomplish far less for the Roundup users,” the judge wrote.

As a result, Bayer has immediately launched a new plan to tackle the long-running legal overhang.

Bayer figures the $2 billion it has set aside for future claims is appropriate, but it will continue to review the provision, CEO Werner Baumann said in a statement Thursday. Bayer will now “reassess ongoing efforts to settle existing claims,” he added.

The company previously committed $9.6 billion to settle with known plaintiffs, wrapping or nearly finalizing 96,000 cases.

RELATED: The top 20 pharma companies by 2020 revenue | 12. Bayer

Meanwhile, Bayer is also rethinking the residential market for Roundup because the “overwhelming majority” of lawsuits have been brought by people who use the weedkiller in the lawn and garden, execs said.

For that market, Bayer is considering replacing the product’s active ingredient glyphosate. The move wouldn’t affect sales, Bayer crop science chief Liam Condon said during a conference call Thursday.

Roundup litigation has haunted Bayer for years, pressuring its stock performance and diverting the large corporation’s attention. Looking forward, ballooning settlement costs could limit Bayer’s ability to invest elsewhere, including its pharma business.

RELATED: Bayer unveils first look at its post-Xarelto, post-Eylea life—and it’s better than expected

In the pharma biz, Bayer is prepping for the expected losses of exclusivity to its top-selling drugs Xarelto and Eylea, which made up nearly half of pharma sales last year. As its internal pipeline looks weak, the company has been acquiring new assets and signing new partnerships to beef up its future prospects.

“We will continue to monitor this and do a quarterly assessment on the potential liability,” Bayer Chief Financial Officer Wolfgang Nickl said of potential change to financial risks during the call.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...